Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Align Technology (ALGN) Prospects Bright, Competition Rife

Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

    PetMed Express Optimistic on New Orders Amid Stiff Rivalry

    PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.

      Anthem to Boost Medicare in Florida With HealthSun Buyout

      Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.

        Medtronic Advances in Pain Therapy With U.S. Intellis Launch

        We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

          Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

          The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

            Amedisys or Chemed: Which is a Better Investment Choice?

            After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

              Why Should Investors Add Amedisys (AMED) to Their Portfolio?

              Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

                Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

                  Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

                  Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

                    Here's Why You Should Add Chemed (CHE) to Your Portfolio

                    Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

                      Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                      BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

                        Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy

                        The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.

                          Boston Scientific MultiSENSE Study on HeartLogic Positive

                          Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

                            Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

                            Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

                              Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                              Neogen (NEOG) rides high on balanced growth across all business segments.

                                Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5

                                Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.

                                  Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

                                  Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

                                    5 MedTech Stocks to Pick for Stellar Returns

                                    While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.

                                      Why the Earnings Streak Will Continue for Amedisys (AMED)

                                      Amedisys (AMED) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.

                                        Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare

                                        Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.

                                          Fresenius Medical Opens Manufacturing Plant in Malaysia

                                          Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

                                            Amedisys Rides High on Strong Prospects Amid Margin Woes

                                            Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.

                                              Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

                                              Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                                                IDEXX Laboratories Rides High on Strong CAG, Global Growth

                                                IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.

                                                  Medtronic Launches StealthStation Technology, Expands in ENT

                                                  Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.